Uses of cardiomyocytes generated from induced pluripotent stem cells by Lu, TY & Yang, L
Cardiomyocyte generation and purifi cation from 
pluripotent embryonic stem cells
Development of the cardiomyocyte lineage from in vitro
cultured embryonic stem (ES) cells has been extensively 
studied in the past decades [1]. Mouse ES cells have been 
widely utilized as an in vitro model to study cardiogenesis, 
as cardiomyocytes were found to spontaneously diﬀ er-
entiate from ES cells after withdrawal of LIF (leukemia 
inhibitory factor), which functions to maintain the pluri-
potency of undiﬀ erentiated mouse ES cells [2-4]. ES cells 
were aggregated into three-dimensional struc tures, termed 
embryoid bodies (EBs), and suspended in media 
containing fetal calf serum. Rhythmically contracting EBs 
with electrophysiological characteristics were present 
after 8 to 10 days of induction [5,6], although the spon-
taneous diﬀ erentiation eﬃ  ciency was quite insuﬃ  cient 
(Table  1). In order to improve the eﬃ  ciency of cardio-
myocyte diﬀ erentiation from ES cells, chemical inducers 
such as dimethyl sulfoxide [7], all-trans retinoic acid [8], or 
5-aza-2’-deoxycytidine [9], which were known to enhance 
cardio myocyte diﬀ erentiation in murine embryonic 
carci noma (EC) P19 cells or mesenchymal stem cells, 
were introduced into mouse ES cell culture. In addition, 
several growth factors, including transforming growth 
factor-β2 [10], Wnt11 [11], Nodal [12], basic ﬁ broblast 
growth factor (bFGF), and bone morphogenetic protein 
(BMP)-2 [13], as well as other reagents such as nitric 
oxide [14], SPARC [15], S100A4 [16], and ascorbic acid 
[17], were used to promote cardiomyocyte diﬀ erentiation 
from mouse ES cells. Th e diﬀ erentiated ES cell cultures 
are heterogeneous and contain undiﬀ erentiated ES cells, 
which could result in teratoma formation after trans-
plantation into the host. In order, therefore, to obtain a 
puriﬁ ed cardiomyocyte population from mouse ES cells, 
several approaches have been developed. Mouse ES cell-
derived EBs were dissociated using collagenase, followed 
with a modiﬁ ed procedure by Isenberg and Klockner in 
1982 to prepare the calcium-tolerant ventricular myo-
cytes [18]. Klug et al. in 1996 [19] reported another trans-
genic selection approach for purifying ES cell-derived 
cardiomyocytes. Th e neomycin-resistant gene driven by 
the cardiac α-myosin heavy chain promoter was stably 
transfected into ES cells. After selection of neomycin-
resistant cells, the resulting cells were shown to be 
cardio myocytes with high purity (>99%) [19]. A similar 
approach was developed using a reporter green ﬂ uores-
cent protein (GFP) driven by the cardiac speciﬁ c α-actin 
promoter. And the GFP-positive cardiomyocytes were 
isolated by ﬂ uorescence-activated cell sorting (FACS) 
[20]. Mouse ES cell-derived cardiomyocytes formed 
stable engrafts in the mouse heart disease model and 
were extensively evaluated for their potential in tissue 
replacement therapy [1,19,21-24].
Seventeen years after the ﬁ rst establishment of mouse 
ES cell lines, the successful isolation and cultivation of ES 
cells of human origin was achieved [25,26]. Human ES 
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(hES) cells can be maintained in vitro for a prolonged 
period (approximately 250 population doublings), and 
have the capacity to diﬀ erentiate into all three germ layer 
cells both in vitro and in vivo [25-27], which makes them 
an unlimited resource for providing various cell types for 
basic research, pharmacological testing, and potential 
thera peutic applications. Similar to mouse ES cells, 
spontaneously contracting cardiomyocytes of hES  cells 
were detected when cultured in 15 to 20% fetal calf serum 
in the absence of the pluripotency-maintaining factor 
basic ﬁ broblast growth factor [28-30]. Methods for 
cardiomyocyte induction from hES cells were mostly 
adapted from those used with mouse ES cells, such as 
addition of 5-aza-2’-deoxycytidine [28,31], and the 
growth factors BMP-2 [32] or BMP-4 [33] to enhance 
cardiomyocyte diﬀ erentiation eﬃ  ciency. In addition, a 
co-culture system has been developed to diﬀ erentiate 
hES cells on top of mouse endoderm-like cells - the 
END-2 cell line - which were found to secrete some 
undeﬁ ned cardiac inducers that promote hES cell 
diﬀ erentiation [34,35]. However, most diﬀ erentiation 
strategies remained suboptimal and could only induce 
approximately 5 to 25% cardiomyocytes from hES cells. 
Progress was made by Yang and colleagues in 2008 [36], 
when a staged protocol was established to induce 
cardiovascular diﬀ erentiation from hES cells by following 
the biology of early heart development, which speciﬁ cally 
yielded over 50% contracting cardiomyocytes after 20 
days of diﬀ erentiation (Figure 1a). In addition, Yang and 
colleagues isolated a multipotent cardiovascular 
progenitor population from hES cells and manipulated 
the speciﬁ cation of these progenitors into cardio-
myocytes, smooth muscle cells and endothelial cells, 
which for the ﬁ rst time established an in vitro system to 
model early human heart formation using hES cells 
(Figure 1b).
As occurs with mouse ES cells, hES cell-derived cell 
cultures contain heterogeneous cell types. How to isolate 
cardiomyocytes from hES cell cultures with high eﬃ   ci-
ency and high purity remains a major challenge. Physical 
enrichment by manual dissection of beating areas or by 
Percoll gradient centrifugation has been utilized for 
cardiomyocyte enrichment [28,35,37]; however, the 
mixed undiﬀ erentiated hES cells within the cardio myo-
cytes prevented the future clinical use of the physically 
enriched cardiomyocytes. Th erefore, genetically engi-
neered hES lines that stably express drug-resistant genes 
within the cardiac cells were developed for cardiomyocyte 
enrichment. For example, a gene encoding an enhanced 
GFP-hyg resistant fusion protein driven by a human 
myosin light chain-2v promoter [38] or by the cardiac-
speciﬁ c human α-myosin heavy chain promoter has been 
introduced into human H9 ES cells for cardiomyocyte 
selection [39]. High purity cardiomyocytes (99%) were 
en riched from hES cells with the selection of GFP-
positive cells or neomycin-resistant cells [39,40]. 
Although the drug selection method easily enriched 
more than 90% cardiomyocytes from hES cells, it has 
several limitations, such as virus integration, drug 
resistance, insuﬃ  cient cardiomyocyte number and the 
diﬃ  culty of engineering each necessary ES cell line, 
which prevent the widespread use of this approach for 
generating a large quantity of healthy cardiomyocytes for 
future clinical use.
Recently, ES cell lines were established from other 
species such as rat [41] and monkey [42,43], and the deri-
va tion of cardiomyocytes from those ES cells described. 
Rat and monkey heart disease models could thus be used 
to evaluate functional improvements obtained following 
auto-transplantation of ES cell-derived cardiomyocytes, 
or the xenotransplantation of human ES/induced pluri-
potent stem (iPS) cell-derived cardiomyocytes. Rat- and 
monkey-derived cardiomyocytes could also be used to 
extensively study their functional characteristics, in vitro 
maturation, in vivo cell survival and functional integration.
Cardiomyocyte diff erentiation from induced 
pluripotent stem cells
Recently, the most exciting breakthrough in stem cell 
biology has been the established feasibility of reprogram-
ming ﬁ broblasts into iPS cells. Both mouse and human 
iPS cells have been generated by transduction of four 
reprogramming factors, Oct4, Sox2, Klf4 and c-Myc 
[44,45], or another set of reprogramming factors, Oct4, 
Sox2, Nanog and Lin28 [46]. iPS cells are identical to ES 
cells morphologically and with regard to their gene 
expression proﬁ les and the capability to form teratomas, 
and can diﬀ erentiate in vitro into three germ layer cell 
types, including cardiomyocytes. Most of the protocols 
for cardiomyocyte induction from iPS cells were naturally 
adapted from ES cell studies. Th e cardiac diﬀ erentiation 
of mouse iPS cells was carried out by Mauritz’s group 
[47], who applied the EB-based diﬀ erentiation protocol 
to mouse iPS cells and found that the ﬁ nal cell culture 
consisted of approximately 55% beating EBs. Mouse iPS 
cells showed comparable cardiac diﬀ erentiation potential 
to ES cells and had similar structural and electro physio-
logical characteristics to ES cell-derived cardiomyocytes. 
Similar results were reported by several other groups 
[48,49]. Although the robust diﬀ erentiation capability of 
mouse iPS cells was demonstrated, cardiac diﬀ erentiation 
from human iPS cells largely remains underdeveloped. In 
2009, two groups demonstrated the derivation of 
functional cardiomyocytes from human iPS cells [50,51]. 
Human iPS cell-derived cardiomyocytes exhibit a fetal-
like phenotype and could be further designated as nodal-, 
atrial-, and ventricular-like cardiomyocyte subtypes [50]. 
However, the frequency of contracting EBs and 
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cardio myocytes was very low (5 to 10%) in those two 
studies. Th erefore, a major challenge was to increase the 
eﬃ  ci ency of cardiomyocyte diﬀ erentiation from human 
iPS cells. By using a similar protocol to that shown in 
Figure  1a, Kattman and colleagues [52] reported the 
highly eﬃ  cient generation of cardiomyocytes from 
human iPS cells with the isolation of kinase insert domain 
receptor (KDR)+platelet-derived growth factor receptor 
(PDGFR-α)+ populations, which gave rise to over 60% 
cardio myocytes after diﬀ erentiation. Interestingly, we 
found that various iPS cell lines, or even diﬀ erent iPS cell 
clones originated from the same ﬁ broblast line, exhibited 
diﬀ erent cardiac diﬀ erentiation eﬃ  ciencies (data not 
published). Th is diﬀ erence may result from the diﬀ erent 
reprogramming strategies or diﬀ erent epigenetic back-
grounds of each iPS cell line. Th e staged protocol shown 
in Figure  1a provides unique access to human iPS cell-
derived cardiovascular progenitor cells, as well as a sub stan-
tial amount of cardiomyocytes, for a variety of studies.
Although cardiomyocytes could be generated from 
human iPS cells, the safety of iPS cell-derived cells must 
be rigorously tested before clinical trials on patients are 
conducted. In addition, iPS cells have been derived from 
other species such as rabbit [53], pig [54-57] and monkey 
[58,59], although cardiomyocyte generation from these 
iPS cells has not been described.
Use of induced pluripotent stem cell-derived 
cardiomyocytes
Human iPS cells provide promising possibilities to bridge 
the gap between basic and clinical research and sus-
tainable solutions for improving public health problems, 
such as human heart diseases. Heart disease is the 
leading cause of death in the United States, including 
coronary heart disease, ischemic heart disease, hyper-
tensive heart disease, valvular heart disease and heart 
failure [60]. While both environmental and genetic factors 
contribute to heart disease, single-gene defects have been 
identiﬁ ed as the direct cause of more than 40 cardio-
vascular disorders, including hypertrophic cardiomyo-
pathy and inherited arrhythmias such as familial long QT 
syndrome (LQTS), short QT syndrome and conduction 
system disorders [61]. Treatments for heart diseases 
include medication, device implantation, tissue ablation 
and eventually heart transplant. Heart disease therapy 
requires the development of patient-speciﬁ c and disease-
speciﬁ c drugs, new cell resources for replacement 
therapy, as well as, ultimately, the engineering of whole 
human heart organs for transplantation. Th e limited 
availability of human cardiomyocytes is, however, a 
major obstacle for such progress. To date, animal models 
and non-human cardiomyocytes are still widely used as a 
major resource in these studies [62-65]. Human iPS 
Figure1. Cardiac diff erentiation from human embryonic stem cells. (a) A staged protocol to induce cardiac diff erentiation from human 
embryonic stem (hES) cells [36]. (b) Modeling early human heart formation using hES cells. hES cells were induced as embryoid bodies using 
the protocol shown in (a). Day 6 embryoid bodies were dissociated and the KDRlow/C-KITneg population represents the multipotent cardiovascular 
progenitor cells with a transcriptional signature of ISL1+, TBX5+ and NKX2.5+. The KDRlow/C-KITneg population was further specifi ed into major 
cardiovascular lineages, including cardiomyocytes, smooth muscle cells and endothelial cells. bFGF, basic fi broblast growth factor; BMP, bone 
morphogenetic protein; DKK1, Dickkopf homolog 1; ES, embryonic stem; KDR, kinase insert domain protein receptor; VEGF, vascular endothelial 
growth factor.
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cell-derived cardiomyocytes are renewable and free of 
the secondary abnormalities that result from end-stage 
disease, comorbidities, and prolonged pharmaceutical 
therapy. Th us, they oﬀ er an unprecedented opportunity 
to generate patient-speciﬁ c lineages for disease modeling, 
drug screening, drug safety testing and potential cell 
replacement therapy of heart disease (Figure 2).
Given the complexities of many heart diseases, the ﬁ rst 
heart disease modeling studies focused on heart diseases 
caused by single gene mutations, which result in the 
disease phenotypes shown by single iPS cell-derived 
cardiomyocytes. To date, cardiac hypertrophy and 
cardiac channelo pathy have been modeled using patient 
iPS cell-derived cardiomyocytes.
Carvajal-Vergara and colleagues [66] generated iPS cell 
lines from patients with LEOPARD syndrome (LS) and 
non-aﬀ ected controls. Approximately 40% of LS patients 
exhibit cardiac hypertrophy. LS iPS cells have a single 
T468M mutation in the gene PTPN11 (protein tyrosine 
phosphatase, non-receptor type 11), the same genetic 
defect as in their parents. Interestingly, the authors 
detected the hypertrophic phenotype in cardiomyocytes 
derived from iPS cells from LS patients, which was 
conﬁ rmed by the enlarged cell size, abnormal sarcomeric 
organization and nuclear localization of NFATC.
Modeling of cardiac channelopathy has been reported 
by several groups. A subtype of cardiac arrhythmias, 
LQTS has been modeled using patient-derived iPS cells. 
Mutations of 12 genes (KCNQ1, KCNH2, SCN5A, ANK2, 
KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, 
AKAP9, and SNTA1) have been identiﬁ ed as the major 
cause of inheritable LQTS. Most of the disease-causing 
genes encode ion channels [67]. LQTS leads to palpita-
tions and a high risk of sudden death due to ventricular 
ﬁ brillation, especially in the young [68-70]. Th ese 
mutations prolong the duration of the ventricular action 
potential, thus increasing the QT interval. Th e most 
common causes of LQTS are mutations in the 
Figure 2. Use of human induced pluripotent stem cell-derived cardiomyocytes. iPS, induced pluripotent stem.
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voltage-gated K+ channel genes, including KCNQ1 (type 
1 LQTS (LQT1)) and KCNH2 (type 2 LQTS (LQT2)), and 
in the voltage-gated Na+ channel gene SCN5A (type 3 
LQTS (LQT3)), which together account for more than 
60% of inherited LQTS cases [67]. Th e abnormalities of 
LQTS can be readily detected at the single cell level with 
electrophysiological assays such as the patch clamp, 
which makes LQTS an ideal heart disease to model with 
iPS cell-derived cardiomyocytes. Several groups have 
thus investigated the feasibility of modeling LQT1 [71], 
LQT2 [72], and Timothy syndrome (LQT3) [73] using 
patient-derived iPS cells. Cardiomyocytes derived from 
iPS cells of those patients recapitulated a delayed rectiﬁ er 
ion current, a typical phenotype detected in patients. 
Some studies have also tested the response of cardio-
myocytes derived from iPS cells of LQT patients to 
pharmaceutical agents [72,73]. All these studies represent 
a promising paradigm to understand the mechanism of 
human inherited heart disease and to develop novel 
drugs for disease therapy.
Th ese ground-breaking discoveries opened a new era in 
the study of heart disease using patient-derived iPS cells. 
However, the molecular etiology of these inherited heart 
diseases has not been clearly addressed. Th e reason lies 
in the diﬃ  culty of enriching a large number of puriﬁ ed 
cardiomyocytes from iPS cell cultures. In addition, single 
cardiomyocytes derived from iPS cells from LS and LQTS 
patients recapitulated only some aspects of the disease 
phenotype in two-dimensional cultures. For example, the 
susceptibility of single cardiomyocytes derived from iPS 
cells of LQTS patients to drug stimulation was diﬀ erent 
to that of the human heart [72]. Given the fact that the 
heart is a complex structured organ with coupled ion 
inﬂ uxes and electrical conductivity, it would be of great 
importance to investigate the mechanisms of heart 
diseases, especially abnormal electrical conductivities in 
cardiac arrhythmias, using a three-dimensional heart 
tissue engineered from cardiomyocytes derived from 
diseased iPS cells.
Another advantage of human iPS/ES cell-derived 
cardiomyocytes is that they can be used as an in vitro 
model for drug safety testing because they originated 
from human and are scalable and reproducible in vitro. 
Th e ﬁ rst attempt at in vitro drug testing was reported by 
Braam and colleagues [74]; hES cell-derived cardiomyo-
cytes revealed dose-dependent responses to 12 cardiac 
and noncardiac drugs, which could lead to the develop-
ment of new drugs for the therapy of heart diseases. 
Th us, human iPS cell-derived cardiomyocytes can 
provide a novel patient-speciﬁ c or disease-speciﬁ c system 
for drug safety testing and drug screening.
Th e potential use of hES cell-derived cardiomyocytes 
for cell replacement therapy was reported several years 
ago [75-77]. hES cell-derived cardiomyocytes were 
intro duced into rodent heart disease models, resulting in 
functional improvements. However, research in this ﬁ eld 
remains underdeveloped, mainly because of poor engraft-
ment eﬃ  ciency after intra-myocardial trans planta tion 
into the myocardial infarction models [76,78]. Studies 
have suggested that the low engraftment eﬃ  ciency may 
be partly due to suboptimal cell resources, poor cell 
delivery, apoptosis of donor cells, and immunological 
rejection [76,79]. In addition, because of the diﬀ erences 
in the physiological and dynamic environments of rodent 
and human hearts, long-term integration of engraftment 
with hES cell-derived cardiomyocytes has not been 
detected. A better strategy is to utilize large animal 
models to study this as the electrophysiological charac-
teristics of rodents are diﬀ erent from those of human. 
One ultimate goal of regenerative medicine is to trans-
plant human iPS cell-derived cardiomyocytes in order to 
repair the damaged heart. However, safety concerns 
regarding virus integra tion during iPS cell reprogram-
ming, the eﬃ  ciency of cardio myocyte genera tion from 
human iPS cell lines, the potential for tumor formation 
from mixed pluripotent iPS cells within the engrafts, and 
the fetal-like phenotype of iPS cell-derived cardio myo-
cytes are major obstacles in this ﬁ eld.
Direct reprogramming of somatic cells into 
cardiomyocytes
Ieda and colleagues reported the direct reprogramming 
of mouse ﬁ broblasts into induced cardiomyocytes (iCMs) 
through the introduction of three factors: Gata4, Mef2c 
and Tbx5 [80]. By comparing microarray data from 
cardiomyocytes and cardiac ﬁ broblasts [81], the authors 
selected 14 candidate factors that play key roles in cardiac 
diﬀ erentiation. Of these 14 candidates, Gata4, Mef2c and 
Tbx5 were identiﬁ ed as the master reprogramming 
factors, responsible for the generation of 5% cTNT (a 
thin ﬁ lament protein speciﬁ cally shown in a contractile 
complex in cardiomyocyte) positive cardiomyocytes from 
cardiac ﬁ broblasts. Interestingly, the iCMs showed 
similarity to mature mouse ventricular cardio myocytes. 
Th is study shed new light on studies of heart development 
and possible clinical applications, yet this system has not 
been extended to human cells and this ﬁ nding has not 
been conﬁ rmed by other groups.
Alternatively, mouse ﬁ broblasts were reprogrammed 
into cardiomyocytes by four iPS cell reprogramming 
factors (Oct4, Sox2, Klf4 and c-Myc) combined with a 
chemically deﬁ ned diﬀ erentiation medium [82]. 
Spontaneously contracting cells were present in the 
culture from day 11. At day 18, over 50% of the cells had 
started beating, and this could reach 80% of cells after 
extended culture. Th e functional characteristics of these 
cells were assayed by calcium ﬂ ux recording and 
electrophysiological tests. Overall, the authors claimed a 
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direct reprogramming of ﬁ broblasts into cardiomyocytes 
without the pluripotent state. However, considering the 
use of iPS cell repro gram ming factors and the very fast 
diﬀ erentiation of mouse ES/iPS cells into cardiomyocytes 
(normally within 5 to 6  days), it is likely this method 
initially converted ﬁ broblast cells into an early 
pluripotent state followed by immediate cardiomyocyte 
commitment. Given the much longer time windows for 
human iPS cell reprogramming and for cardiomyocyte 
diﬀ erentiation from human ES/iPS cells, conﬁ rmation of 
this direct reprogramming strategy with human cells 
would provide more details on the underlying 
mechanisms.
To date, iPS cells have been generated from various 
somatic cell types, including ﬁ broblasts [44], blood [83,84], 
melanocytes [85], pancreatic β cells [86], and neural 
progenitors [87,88]. Interestingly, early passage iPS cells 
were found to retain a transient epigenetic memory of 
their original tissue type, which inﬂ uenced their 
subsequent diﬀ erentiation capability [89,90]. Studies 
from Srivastava’s group [80] showed that iCMs exhibit a 
mature ventricular cardiomyocyte phenotype and heart-
derived ﬁ broblasts gave rise to two-fold more iCMs than 
tail-derived dermal ﬁ broblasts, indicating that the 
epigenetic memory of ﬁ broblasts could aﬀ ect the 
derivation of iCMs. All these studies strongly suggested 
that the tissue origin or tissue memory of ﬁ broblasts 
could aﬀ ect the reprogramming of iPS cells, as well as the 
further diﬀ erentiation of iPS cells into various lineages.
Conclusion
Spontaneously beating cardiomyocytes have been 
detected from ES cells cultured in the absence of factors 
supporting self-renewal. For the past decade, however, 
the eﬃ  ciency of generation and purity of ES cell-derived 
cardio myocytes remain largely unsatisfactory. Recent 
progress established a staged protocol to eﬃ  ciently 
induce cardiac diﬀ erentiation from ES cells by recapitu-
lating the early events of heart formation (Figure  1a), 
which for the ﬁ rst time provided a large amount of 
multipotent cardio vascular progenitor cells. Th us, ES 
cells can be used to model early human heart formation 
and be utilized as a tool to address early heart 
determination and speciﬁ  cation in vitro. However, ethical 
issues with hES cells have prevented the widespread use 
of ES cells and their diﬀ erentiated progenies. With the 
breakthrough of iPS cells, pluripotent stem cells can be 
easily converted from somatic cells without requiring 
embryos. Most impor tantly, iPS cell technology opens a 
new era in obtaining unlimited patient-speciﬁ c lineage 
cells, which will harbor the same genetic defects as the 
patients. Cardiomyocytes derived from patient-speciﬁ c 
iPS cells would greatly accelerate the understanding of 
human inherited heart diseases and beneﬁ t drug 
development and potential cell replacement therapies for 
human heart disease. Although issues such as virus 
safety, tumor formation after trans plantation and non-
puriﬁ ed donor cells are current hurdles to the direct use 
of iPS cell-derived cardiomyo cytes for clinical use, iPS 
cells so far provide the most promising resource for 
scientists to eventually bridge the gap between basic 
research and sustainable solutions for the treatment of 
human heart disease.
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